HIIT Following Breast Cancer Chemotherapy
NCT05913713
Breast Cancer, Breast Diseases
Gainesville, Florida, United States
View Trial DetailsNCT Number: NCT01991340
This observational study will assess the safety of Herceptin (trastuzumab) in patients with HER2-positive breast cancer in routine clinical practice. Eligible patients will be followed for up to 4 years.
Looking for future studies?
Notify Me18 year and older
All sexes
Observational
Algiers, Algeria
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Time frame: up to approximately 4.5 years
Time frame: up to approximately 4.5 years
Time frame: up to approximately 4.5 years
Time frame: up to approximately 4.5 years
Looking for future studies?
Notify MeHoffmann-La Roche
Industry
H.E.R.O.S. Study: Observational Study to Assess the Cardiac Safety Profile of Trastuzumab in Patients With HER2-positive Breast Cancer.
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05913713
Breast Cancer, Breast Diseases
Gainesville, Florida, United States
View Trial DetailsNCT05498155
Breast Cancer, Breast Diseases
Loveland, Colorado, United States
View Trial DetailsNCT05607849
Breast Cancer, Breast Diseases
Nantes, France
View Trial DetailsNCT03697577
Breast Cancer, Breast Diseases
The Bronx, New York, United States
View Trial Details